Systemic lupus erythematosus in a multiethnic US cohort (LUMINA) XXXI: Factors associated with patients being lost to follow-up

Lupus

Volumn 15, Issue 1, 2006, Pages 19-25

  Bertoli, A M ^a   Fernandez M ^a   Calvo Alen J ^a   Vila L M ^b   Sanchez, M L ^a   Reveille, J D ^c   Alarcón, Graciela S ^a,d  

^a University of Alabama at Birmingham   (United States)

^b UNIVERSITY OF PUERTO RICO SCHOOL OF MEDICINE   (Puerto Rico)

^c UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^d 830 Faculty Office Tower ^*  (United States)

Author keywords

Cohort study; Loss to follow up; Systemic lupus erythematosus

Indexed keywords

ADULT; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ACTIVITY; ETHNIC DIFFERENCE; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; SOCIAL SUPPORT; SYSTEMIC LUPUS ERYTHEMATOSUS; UNITED STATES;

ADULT; AFRICAN AMERICANS; CONFIDENCE INTERVALS; DISEASE PROGRESSION; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; FOLLOW-UP STUDIES; HISPANIC AMERICANS; HUMANS; INCIDENCE; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; ODDS RATIO; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS; UNITED STATES;

EID: 33144487417     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1191/0961203306lu2257oa     Document Type: Article

References (36)

1. Kraus JF, Gardner L, Collins J, Sorock G, Volinn E. Design factors in epidemiologic cohort studies of work-related low back injury or pain. Am J Ind Med 1997; 32: 153-163.
2. Goldacre M. The role of cohort studies in medical research. Pharmacoepidemiolo Drug Saf 2001; 10: 5-11.
3. Grimes DA, Schulz KF. Cohort studies: marching towards outcomes. Lancet 2002; 259: 341-345.
4. Touloumi G, Babiker AG, Pocock SJ, Darbyshire JH. Impact of missing data due to drop-outs on estimators for rates of change in longitudinal studies: a simulation study. Stat Med 2001; 20: 3715-3728.
5. Schulz KF, Grimes DA. Sample size slippages in randomised trials: exclusions and the lost and wayward. Lancet 2002; 359: 781-785.
6. Sprague S, Leece P, Bhandari M et al. Limiting loss to follow-up in a multicenter randomized trial in orthopedic surgery. Control Clin Trials 2003; 24: 719-725.
7. Gladman DD, Koh DR, Urowitz MB, Farewell VT. Lost-to-follow-up study in systemic lupus erythematosus (SLE). Lupus 2000; 9: 363-367.
8. Moss KE, Ioannou Y, Sultan SM, Haq I, Isenberg DA. Outcome of a cohort of 300 patients with systemic lupus erythematosus attending a dedicated clinic for over two decades. Ann Rheum Dis 2002; 61: 409-413.
9. Gripenberg M, Helve T. Outcome of systemic lupus erythematosus. A study of 66 patients over 7 years with special reference to the predictive value of anti-DNA antibody determinations. Scand J Rheumatol 1991; 20: 104-109.
10. Stoll T, Sutcliffe N, Mach J, Klaghofer R, Isenberg DA. Analysis of the relationship between disease activity and damage in patients with systemic lupus erythematosus - a 5-year prospective study. Rheumatology (Oxford) 2004; 43: 1039-1044.
11. Uribe AG, Alarcon GS, Sanchez ML et al. Systemic lupus erythematosus in three ethnic groups. XVIII. Factors predictive of poor compliance with study visits. Arthritis Rheum (Arthritis Care Res) 2004; 51: 258-263.
12. Alarcon GS, Friedman AW, Straaton KV et al. Systemic lupus erythematosus in three ethnic groups: III. A comparison of characteristics early in the natural history of the LUMINA cohort. LUpus in Minority populations: NAture versus Nurture. Lupus 1999; 8: 197-209.
13. Vilá LM, Alarcón GS, McGwin G Jr et al. Early clinical manifestations, disease activity and damage of systemic lupus erythematosus among two distinct US Hispanic subpopulations. Rheumatology 2004; 43: 358-363.
14. Tan EM, Cohen AS, Fries JF et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271-1277.
15. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997; 40: 1725.
16. Reveille JD, Moulds JM, Ahn C et al. Systemic lupus erythematosus in three ethnic groups: I. The effects of HLA class II, C4, and CR1 alleles, socioeconomic factors, and ethnicity at disease onset. LUMINA Study Group. Lupus in minority populations, nature versus nurture. Arthritis Rheum 1998; 41: 1161-1172.
17. U.S. Department of Commerce, Bureau of the Census. Current population reports, Series P-23, No. 28 and Series P-60, No. 68 and subsequent years. Housing and Household Economic Statistics Division, 1995.
18. Cohen S, Mermelstein R, Kamarck T, Hoberman HN. Measuring the functional components of social support. In Sarason IG, Sarason BR eds. Social support: theory, research and applications. Martinus Nijhoff, 1985: 73-94.
19. Engle EW, Callahan LF, Pincus T, Hochberg MC. Learned helplessness in systemic lupus erythematosus: analysis using the Rheumatology Attitude Index. Arthritis Rheum 1990; 33: 281-286.
20. Pilowsky I. Dimensions of illness behavior as measured by the Illness Behavior Questionnaire: a replication study. J Psychosom Res 1993; 37: 53-62.
21. Ware JE Jr, Sherbourne CD. The MOS 36-item short form health survey (SF-36): I. Conceptual framework and item selection. Med Care 1992; 30: 473-483.
22. Ware JE, Kosinski M, Keller SD. SF-36 physical and mental health summary scales: a user's manual The Health Institute, New England Medical Center, 1994.
23. Liang MH, Socher SA, Larson MG, Schur PH. Reliability and validity of six systems for the clinical assessment of disease activity in systemic lupus erythematosus. Arthritis Rheum 1989; 32: 1107-1118.
24. Gladman DD, Goldsmith CH, Urowitz MB et al. The Systemic Lupus International Collaborating Clinics/American College of Rheumatology (SLICC/ACR) Damage Index for Systemic Lupus Erythematosus International Comparison. J Rheumatol 2000; 27: 373-376.
25. Kristman V, Manno M, Cote P. Loss to follow-up in cohort studies: how much is too much? Eur J Epidemiol 2004; 19: 751-760.
26. Norquist BM, Goldberg BA, Matsen FAI. Challenges in evaluating patients lost to follow-up in clinical studies of rotator cuff tears. J Bone Joint Surg Am 2000; 82: 838-842.
27. Wildner M. Lost to follow-up. J Bone Joint Surg Br 1995; 77: 657.
28. Bernatsky S, Pineau C, Joseph L, Clarke A. Adherence to ophthalmologic monitoring for antimalarial toxicity in a lupus cohort. J Rheumatol 2003; 30: 1756-1760.
29. Corbie-Smith G, Thomas SB, Williams MV, Moody-Ayers S. Attitudes and beliefs of African Americans toward participation in medical research. J Gen Intern Med 1999; 14: 537-546.
30. Austin JS, Ambrose RF, Young PK, Moreland LW, Alarcon GS. Rheumatoid arthritis patients and clinical drugs trials: a case-control study. Arthritis Care Res 1991; 4: 22-26.
31. Mosley-Williams A, Lumley MA, Gillis M, Leisen J, Guice D. Barriers to treatment adherence among African American and white women with systemic lupus erythematosus. Arthritis Rheum (Arthritis Care Res) 2002; 47: 630-638.
32. Bruce IN, Gladman DD, Urowitz MB. Factors associated with refractory renal disease in patients with systemic lupus erythematosus: the role of patient nonadherence. Arthritis Care Res 2000; 13: 406-408.
33. McElhone K, Walker J, Abbott J et al. Treatment adherence in systemic lupus erythematosus (SLE). Lupus 2005; 14: 245.
34. Mendoza-Grado V, Salvador RJ. Are chicanes the same as mexicans? A taxonomy. Retrieved 2005, from http://mbeaworg/resources/history/ mexicanamerican html
35. Shumaker SA, Dugan E, Bowen DJ. Enhancing adherence in randomized controlled clinical trials. Control Clin Trials 2000; 21: 226S-232S.
36. Mihalko SL, Brenes GA, Farmer DF, Katula JA, Balkrishanan R, Bowen DJ. Challenges and innovations in enhancing adherence. Control Clin Trial 2004; 25: 447-457.